Assessing patient satisfaction following treatment with sodium glucose co-transporter 2 inhibitor for type 1 diabetes mellitus
Not Applicable
- Conditions
- type 1 diabetes mellitus
- Registration Number
- JPRN-UMIN000040487
- Lead Sponsor
- Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, Kimitsu Chuo Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who do not agree to participate in the study Patients judged by the attending physician that there is no indication for SGLT2 inhibitor administration
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes of Satisfaction score measured in the DTSQ by five possible responses (varying from -2; very dissatisfied, to +2; very satisfied, varying by integers), both previous and three months subsequent to ipragliflozin administration.
- Secondary Outcome Measures
Name Time Method To assess safety and efficacy, the data prior to and three months subsequent of the oral administration of the SGLT2 inhibitor were collected such as body mass index, body composition, glycated hemoglobin (HbA1c), and glycemic variability were obtained from flash glucose monitoring (FGM) systems (Free Style Libre; Abbott Diabetes Care, Witney, UK) measured for three months prior to and three months subsequent of the oral administration of the SGLT2 inhibitor. Retrospective data included the insulin dose, the number of severe hypoglycemia incidence requiring assistance, diabetic ketoacidosis, and other side effects.